Cite
HARVARD Citation
Rimassa, L. et al. (2018). Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet oncology. 19 (5), pp. 682-693. [Online].